このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Oragenics マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Mike Redmond

最高経営責任者

US$343.8k

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	8.7yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Mike Redmond (63 yo)

less than a year

在職期間

US$343,800

報酬

Mr. Joseph Michael Redmond, also known as Mike, serves as President of Oragenics, Inc. since December 28, 2023 and also serves as its Interim Principal Executive Officer since February 12, 2024 and served...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Charles Pope	Executive Chairman	14.1yrs	US$196.75k	0.57% $ 32.7k
Joseph Redmond	President & Interim Principal Executive Officer	less than a year	US$343.80k	データなし
Janet Huffman	CFO, Secretary & Treasurer	1.3yrs	US$365.40k	0.33% $ 19.2k
James Kelly	Chief Medical Officer & Member of Scientific Advisor	less than a year	データなし	データなし
William Peacock	Chief Clinical Officer	less than a year	データなし	データなし

0.4yrs

平均在職期間

63yo

平均年齢

経験豊富な経営陣: OGENの経営陣は経験豊富とはみなされません ( 0.3年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Charles Pope	Executive Chairman	14.1yrs	US$196.75k	0.57% $ 32.7k
James Kelly	Chief Medical Officer & Member of Scientific Advisor	less than a year	データなし	データなし
John Gandolfo	Independent Director	less than a year	US$25.13k	0% $ 0
Frederick Telling	Independent Director	14.1yrs	US$156.75k	0.84% $ 48.1k
Alan Dunton	Independent Director	13.3yrs	US$140.50k	0.57% $ 33.0k
Bruce Cassidy	Independent Director	less than a year	US$25.13k	7.91% $ 454.9k
Robert Koski	Independent Director	15.1yrs	US$134.25k	0.62% $ 35.8k
Kimberly Murphy	Director	4.2yrs	US$592.15k	0.56% $ 32.1k
Timothy Cooke	Member of Scientific Advisor	no data	データなし	データなし
David Zarley	Member of Scientific Advisor	no data	データなし	データなし
Terrence Cochrane	Member of Scientific Advisor	no data	データなし	データなし

8.7yrs

平均在職期間

70yo

平均年齢

経験豊富なボード: OGENの取締役会は経験豊富であると考えられます ( 8.6年の平均在任期間)。

Oragenics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Oragenics, Inc. Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc., Annual General Meeting, Dec 14, 2023

Oragenics Announces Directorate Appointments

Insufficient new directors

Recent updates

Oragenics, Inc. has completed a Follow-on Equity Offering.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics Announces NYSE American Acceptance of Plan of Compliance

Oragenics, Inc. Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial

First quarter 2024 earnings released: US$0.70 loss per share (vs US$1.41 loss in 1Q 2023)

Full year 2023 earnings released: US$9.18 loss per share (vs US$7.11 loss in FY 2022)

Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $2.1 million.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc. Prepares for Phase II Clinical Trials to Treat Concussion

New major risk - Share price stability

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. (NYSEAM:OGEN) completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Third quarter 2023 earnings released: US$0.85 loss per share (vs US$1.99 loss in 3Q 2022)

Oragenics, Inc., Annual General Meeting, Dec 14, 2023

Oragenics Announces Directorate Appointments

Oragenics, Inc. (NYSEAM:OGEN) entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Second quarter 2023 earnings released: US$1.51 loss per share (vs US$1.85 loss in 2Q 2022)

Oragenics, Inc. announced that it has received $0.85 million in funding

Oragenics, Inc. Announces the Award of Grant from CQDM for the Collaborative Development of a Variant-Agnostic COVID-19 Protein Subunit Vaccine Candidate

Insufficient new directors

Oragenics, Inc. Regains Compliance with NYSE American

Oragenics, Inc. Reports Favorable Toxicology Results for Its Covid-19 Intranasal Vaccine Candidate

Oragenics, Inc. Receives NYSE American Notice Regarding Compliance with Section 1003(f)(v)

Oragenics, Inc. Announces Board Changes

Oragenics, Inc. Appoints Kimberly Murphy as Secretary and Treasurer

Oragenics, Inc. Announces Resignation of Michael Sullivan as Chief Financial Officer, Effective from December 14, 2022

Price target increased to US$2.25

Oragenics, Inc., Annual General Meeting, Dec 16, 2022

Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

Price target increased to US$2.25

Oragenics, Inc. Appoints Kimberly M. Murphy as Chief Executive Officer

Oragenics Announces Publication of Positive Data for Its NT-Cov2-1 Intranasal Covid-19 Vaccine Candidate in Scientific Reports

Price target decreased to US$2.25

Executive Chairman recently bought US$66k worth of stock

Price target decreased to US$2.25

Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript

Oragenics, Inc. Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations SARS-CoV-2 Vaccine Candidate

Price target increased to US$2.25

Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

Executive Chairman exercised options to buy US$110k worth of stock.

New 90-day high: US$1.30

Oragenics, Inc. Provides Update on Competitive Positioning of Terra CoV-2 Vaccine Against SARS-CoV-2, Expects to File IND in Third Quarter of 2021

New 90-day high: US$0.62

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $6.5 million.

Insider recently sold US$2.1m worth of stock

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $5.25 million.

New 90-day low: US$0.47

New 90-day low: US$0.54

Oragenics, Inc. Announces Receipt of Feedback to Its Type B Pre-Ind Meeting Request from the U.S. Food and Drug Administration

New 90-day low: US$0.56

Oragenics, Inc. (AMEX:OGEN) acquired Noachis Terra Inc. from Joseph Hernandez for $6.6 million.

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24